Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
This study of 142 men with metastatic castration-resistant prostate cancer (mCRPC) found that nuclear-localized AR-V7 protein in circulating tumor cells can be an indication of whether or not these patients have better survival rates with taxane chemotherapy compared to androgen receptor signaling (ARS)-directed therapy.
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
This study of 161 men with metastatic castration-resistant prostate cancer (mCRPC) validates circulating tumor cells (CTC) nuclear expression of AR-V7 protein as a treatment-specific biomarker that is associated with better survival rates for patients on taxane therapy versus androgen receptor signaling (ARS)-directed therapy.
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort
This study found that the cell cycle progression (CCP) score (known as Prolaris) may aid in treating men with clinically localized prostate cancer and is the strongest independent predictor of prostate cancer mortality.
Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry
This prospective study looked at the impact of the cell cycle progression (CCP) test (Prolaris) on physician recommendations and found that the test results led to meaningful changes in treatment plans.
Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance
This study found that the clinical cell-cycle risk (CCR) score threshold is effective in segmenting patients into low- and high-risk groups for 10-year prostate cancer mortality. As a result, the research concludes that CCR (Polaris) may lead to more men being appropriately categorized into active surveillance.
Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy
This study found that patients with a high Decipher genomic classifier score “were more than twice as likely than patients with a lower score to experience biochemical and clinical progression and receive salvage hormone therapy.” Patients with higher scores who were treated early had much better outcomes than those treated later in their disease progression, […]
Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men
Like most research, the Decipher genomic classifier test had originally been studied in Caucasian men. This study looked at its accuracy for predicting metastasis and prostate cancer mortality in African American men and found the Decipher test may actually work better in African American men.
Individual patient-level meta-analysis of the performance of the Decipher Genomic Classifier in high-risk men after prostatectomy to predict development of metastatic disease
This research analyzed five studies of nearly 1,000 men and found the Decipher RP test to be effective in predicting outcomes of patients across all subgroups, regardless of demographics, clinical factors, and treatment approaches.
A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Feature
This real-world multi-institutional study found the Genomic Prostate Score Test is an effective, independent predictor of adverse pathology at surgery and provided patients with greater confidence and assurance in their decision.
Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy, Adverse Surgical Pathology in a Racially Diverse Population of Men
This study of 431 men found that the GPS test is a strong, independent measure of prostate cancer aggressiveness in both African American and Caucasian men as well as an effective test in predicting the recurrence of prostate cancer after a radical prostatectomy.